{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:18Z","timestamp":1790050938848,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Federal Joint Committee, Innovation Committee","award":["01VSF18051"],"award-info":[{"award-number":["01VSF18051"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Survivors of myocardial infarction have an elevated risk of long-term mortality. We sought to evaluate guideline-directed medical treatment and its impact on long-term mortality in survivors of ST-elevation myocardial infarction (STEMI) according to their chronic kidney disease (CKD) stage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using German health insurance claims data, 157\u00a0663 hospitalized survivors of STEMI were identified. Regarding different CKD stages, we retrospectively analysed the filled prescriptions of platelet inhibitors (PAI)\/oral anticoagulation, statins, beta-blocker and angiotensin-converting enzyme inhibitors\/angiotensin II type 1 receptor antagonists (ACE-I\/AT1-A) and their association with long-term mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Prescription rates for all four guideline-directed drugs were highest in patients without or with mild CKD and lowest in patients on dialysis. They dropped from 73.4% to 39.2% in patients without CKD and from 47.1% to 29% in patients on dialysis within the 5-year follow-up period. Mortality rates were dramatically increased in patients with CKD compared with patients without CKD (5-year mortality: no CKD, 16.7%; CKD stage 3, 47.1%; CKD stage 5d, 69.7%). Filled prescriptions of at least one drug class [one drug: hazard ratio (HR) 0.70, 95% confidence interval (95% CI) 0.66\u20130.74; four drugs: HR 0.28, 95% CI 0.27\u20130.30; P\u00a0&amp;lt;\u00a0.001 for both] as well as the distinct drug classes (statins: HR 0.55, 95% CI 0.54\u20130.56; ACE-I\/AT1-A: HR 0.68, 95% CI 0.67\u20130.70; beta-blocker: HR 0.87, 95% CI 0.85\u20130.90; PAI\/oral anticoagulation: HR 0.97, 95% CI 0.95\u20131.00; all P\u00a0&amp;lt;\u00a0.05) improved long-term mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>An improved long-term guideline-recommended drug therapy after STEMI regardless of renal impairment might lead to beneficial effects on long-term mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfad219","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:42:47Z","timestamp":1693892567000},"page":"1947-1956","source":"Crossref","is-referenced-by-count":2,"title":["Contemporary secondary prevention in survivors of ST-elevation myocardial infarction with and without chronic kidney disease: a retrospective analysis"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-5117","authenticated-orcid":false,"given":"Christiane","family":"Engelbertz","sequence":"first","affiliation":[{"name":"Department of Cardiology I \u2013 Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster , Cardiol, Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-9192","authenticated-orcid":false,"given":"Jannik","family":"Feld","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of Muenster , Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Makowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology I \u2013 Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster , Cardiol, Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Cardiology I \u2013 Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster , Cardiol, Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-6259","authenticated-orcid":false,"given":"Christian","family":"G\u00fcnster","sequence":"additional","affiliation":[{"name":"AOK Research Institute , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[{"name":"AOK Research Institute , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruhnke","sequence":"additional","affiliation":[{"name":"AOK Research Institute , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-683X","authenticated-orcid":false,"given":"Joachim","family":"Ger\u00df","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of Muenster , Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-1609","authenticated-orcid":false,"given":"Holger","family":"Reinecke","sequence":"additional","affiliation":[{"name":"Department of Cardiology I \u2013 Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster , Cardiol, Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-2995","authenticated-orcid":false,"given":"Jeanette","family":"K\u00f6ppe","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of Muenster , Muenster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"2023103104592110900_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12872-017-0482-9","article-title":"Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review","volume":"17","author":"Johansson","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2023103104592110900_bib2","doi-asserted-by":"crossref","first-page":"e013570","DOI":"10.1136\/bmjopen-2016-013570","article-title":"Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011","volume":"7","author":"Gitsels","year":"2017","journal-title":"BMJ Open"},{"key":"2023103104592110900_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2023103104592110900_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA Guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"2023103104592110900_bib5","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","article-title":"Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014","volume":"38","author":"Szummer","year":"2017","journal-title":"Eur Heart J"},{"key":"2023103104592110900_bib6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2011.522","article-title":"Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction","volume":"305","author":"Jernberg","year":"2011","journal-title":"JAMA"},{"key":"2023103104592110900_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40256-020-00427-9","article-title":"Optimal medical therapy prescription in patients with acute coronary syndrome in the Netherlands: a multicenter pilot registry","volume":"21","author":"Hoedemaker","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2023103104592110900_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40256-019-00361-5","article-title":"Long-term quality of prescription for ST-segment elevation myocardial infarction (STEMI) patients: a real world 1-year follow-up study","volume":"20","author":"Bruggmann","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"2023103104592110900_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.amjcard.2017.11.002","article-title":"Effect of optimal medical therapy at discharge in patients with reperfused ST-segment elevation myocardial infarction on 1-year mortality (from the Regional RESCUe Registry)","volume":"121","author":"Tomasevic","year":"2018","journal-title":"Am J Cardiol"},{"key":"2023103104592110900_bib10","doi-asserted-by":"crossref","first-page":"e005879","DOI":"10.1161\/CIRCOUTCOMES.119.005879","article-title":"Treatments and mortality trends in cases with and without dialysis who have an acute myocardial infarction: an 18-year nationwide experience","volume":"12","author":"Szummer","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023103104592110900_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12872-022-02573-1","article-title":"Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry","volume":"22","author":"Schmucker","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"2023103104592110900_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/jamainternmed.2015.6403","article-title":"Exclusion of patients with kidney disease from cardiovascular trials","volume":"176","author":"Ishida","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2023103104592110900_bib13","doi-asserted-by":"crossref","first-page":"E112","DOI":"10.1002\/ccd.27860","article-title":"The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry","volume":"93","author":"Ge","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2023103104592110900_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.11.026","article-title":"Management and outcomes of acute myocardial infarction in patients with chronic kidney disease","volume":"227","author":"Smilowitz","year":"2017","journal-title":"Int J Cardiol"},{"key":"2023103104592110900_bib15","doi-asserted-by":"crossref","first-page":"e002664","DOI":"10.1161\/JAHA.115.002664","article-title":"Decade long trends (2001-2011) in duration of pre-hospital delay among elderly patients hospitalized for an acute myocardial infarction","volume":"5","author":"Makam","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2023103104592110900_bib16","doi-asserted-by":"crossref","first-page":"e010394","DOI":"10.1161\/JAHA.118.010394","article-title":"Temporal trends in utilization of cardiac therapies and outcomes for myocardial infarction by degree of chronic kidney disease: a report from the NCDR Chest pain-MI Registry","volume":"7","author":"Bagai","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2023103104592110900_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7196\/SAMJ.7798","article-title":"Self-reported use of evidence-based medicine and smoking cessation 6\u20139 months after acute coronary syndrome: a single-centre perspective","volume":"104","author":"Griffiths","year":"2014","journal-title":"S Afr Med J"},{"key":"2023103104592110900_bib18","doi-asserted-by":"crossref","first-page":"e12240","DOI":"10.1111\/1755-5922.12240","article-title":"Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: results from the CAPS study","volume":"35","author":"Cordero","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"2023103104592110900_bib19","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023103104592110900_bib20","doi-asserted-by":"crossref","first-page":"175394472091207","DOI":"10.1177\/1753944720912071","article-title":"Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial","volume":"14","author":"Mariani","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2023103104592110900_bib21","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023103104592110900_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023103104592110900_bib23","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1253\/circj.CJ-20-1115","article-title":"Impact of chronic kidney disease on in-hospital and 3-year clinical outcomes in patients with acute myocardial infarction treated by contemporary percutaneous coronary intervention and optimal medical therapy\u2014insights from the J-MINUET study","volume":"85","author":"Hashimoto","year":"2021","journal-title":"Circ J"},{"key":"2023103104592110900_bib24","doi-asserted-by":"crossref","first-page":"e008995","DOI":"10.1161\/CIRCOUTCOMES.122.008995","article-title":"Guideline-directed medical therapy attainment and outcomes in dialysis-requiring versus nondialysis chronic kidney disease in the ISCHEMIA-CKD trial","volume":"15","author":"Mathew","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023103104592110900_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40256-019-00338-4","article-title":"Do patients need lifelong \u03b2-blockers after an uncomplicated myocardial infarction","volume":"19","author":"Zeitouni","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"2023103104592110900_bib26","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"2023103104592110900_bib27","first-page":"CD008834","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2023103104592110900_bib28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.120.045695","article-title":"Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome: still sacrosanct or is reappraisal warranted","volume":"142","author":"Jacobsen","year":"2020","journal-title":"Circulation"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad219\/51725186\/sfad219.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/11\/1947\/52692096\/sfad219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/11\/1947\/52692096\/sfad219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:40:43Z","timestamp":1698734443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/11\/1947\/7259931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,4]]},"published-print":{"date-parts":[[2023,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad219","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,9,4]]}}}